The global cell expansion market generated US $ 13.06 billion in 2020 and is estimated to garner US $ 39.03 billion by 2030, witnessing a CAGR of 11.6% from 2021. These findings are part of a report published by Allied Market Research.

The report highlighted the drivers and opportunities for the sector. The rise in prevalence of chronic diseases, increase in government investments for cell-based research and focus on R&D for cell-based therapies drive the growth of the global cell expansion market. However, the high cost of cell-based therapies and ethical concerns regarding research in cell biology hinder the market growth. On the other hand, focus on personalized medicine creates new opportunities in the coming years.

Covid-19 had a positive impact on the sector. During the Covid-19 pandemic, the demand for cell expansion products such as consumables including sera, media, and reagent and instrument increased considerably. As per the WHO ICTRP and the NIH ClinicalTrials.gov databases, 27 clinical investigations regarding MSC-based cell therapy approaches started in China since the outbreak of the COVID-19. Moreover, there has been a huge number of academic and industry trials conducted across the world. Stem cell research is one of the crucial applications of cell expansion and stem cell-based therapies showed considerable potential in studying Covid-19. So, the market for cell expansion experienced a positive impact.

Based on application, the tissue engineering & regenerative medicine segment accounted for the highest share in 2020, contributed to nearly two-fifths of the global cell expansion market, and is expected to continue its leadership status during the forecast period. This is due to recent advancements and increased funding for this application. However, the cancer research segment is estimated to witness the highest CAGR of 12.7% from 2021 to 2030, owing to a surge in the prevalence of cancer and cancer-related research.

Based on end-users, the pharmaceutical & biotechnology companies segment held the highest share in 2020, contributing to more than three-fifths of the global cell expansion market, and is estimated to maintain its lead position during the forecast period. Moreover, this segment is projected to manifest the fastest CAGR of 12.3% from 2021 to 2030. This is attributed to broadening the horizon of cell-based therapeutics in the healthcare industry, the high burden of chronic diseases, and the rise in R&D activities in the pharmaceutical and biotechnology industries. The research also analyzes the segments including research institutes and others.

Based on region, North America accounted for the highest market share in terms of revenue in 2020, accounting for more than two-fifths of the global cell expansion market, and is expected to continue its dominance by 2030. This is due to the development of animal-component free media, the presence of automated cell culture systems, and the well-established healthcare demand for biopharmaceutical products. Asia-Pacific is projected to portray the  fastest CAGR of 13.2 per cent during the forecast period, owing to the constant expansion of the healthcare infrastructure, economic development, and low operating costs.